{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:52Z","timestamp":1791912472441,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JPJSBP 120217720"],"award-info":[{"award-number":["JPJSBP 120217720"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008884","name":"Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering","doi-asserted-by":"publisher","award":["technology exchange program"],"award-info":[{"award-number":["technology exchange program"]}],"id":[{"id":"10.13039\/501100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-03804-y","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:27:08Z","timestamp":1724412428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Hiroya","family":"Ohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kikutsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"3804_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-2004-829595","volume":"24","author":"VC Juel","year":"2004","unstructured":"Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24:75\u201381. https:\/\/doi.org\/10.1055\/s-2004-829595.","journal-title":"Semin Neurol"},{"issue":"1","key":"3804_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation. 2022;19(1):89. https:\/\/doi.org\/10.1186\/s12974-022-02448-4.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"3804_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"issue":"6","key":"3804_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","volume":"53","author":"J Roper","year":"2017","unstructured":"Roper J, Fleming ME, Long B, Koyfman A. Myasthenia gravis and crisis: Evaluation and management in the emergency department. J Emerg Med. 2017;53(6):843\u201353. https:\/\/doi.org\/10.1016\/j.jemermed.2017.06.009.","journal-title":"J Emerg Med"},{"issue":"3","key":"3804_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: First approval. Drugs. 2022;82(3):341\u20138. https:\/\/doi.org\/10.1007\/s40265-022-01678-3.","journal-title":"Drugs"},{"issue":"23","key":"3804_CR6","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373. https:\/\/doi.org\/10.1212\/WNL.0000000000007600.","journal-title":"Neurology"},{"issue":"12","key":"3804_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/1744666X.2022.2136167","volume":"18","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Uzawa A, Murai H. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Expert Rev Clin Immunol. 2022;18(12):1207\u201315. https:\/\/doi.org\/10.1080\/1744666X.2022.2136167.","journal-title":"Expert Rev Clin Immunol"},{"key":"3804_CR8","doi-asserted-by":"publisher","first-page":"175628642412548","DOI":"10.1177\/17562864241254895","volume":"17","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yang M, Luo T, Du X, Wang Z, Huang X, et al. Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report. Ther Adv Neurol Disord. 2024;17:17562864241254896. https:\/\/doi.org\/10.1177\/17562864241254895.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"3804_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/mus.28178","volume":"70","author":"F Sun","year":"2024","unstructured":"Sun F, Batra A, Dickson D, Li Y, Wu EL. Efgartigimod infusion in the treatment regimen for myasthenic crisis: A case report. Muscle Nerve. 2024;70(2):290\u20132. https:\/\/doi.org\/10.1002\/mus.28178.","journal-title":"Muscle Nerve"},{"key":"3804_CR10","doi-asserted-by":"publisher","first-page":"9455237","DOI":"10.1155\/2024\/9455237","volume":"2024","author":"O Alhaj Omar","year":"2024","unstructured":"Alhaj Omar O, Diel NJ, Gerner ST, M\u00fcck A, Huttner HB, Kr\u00e4mer-Best HH. Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis. Case Rep Neurol Med. 2024;2024:9455237. https:\/\/doi.org\/10.1155\/2024\/9455237.","journal-title":"Case Rep Neurol Med"},{"key":"3804_CR11","doi-asserted-by":"publisher","first-page":"1321058","DOI":"10.3389\/fneur.2024.1321058","volume":"15","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Ohashi S, Watanabe T, Kakinuma Y, Kinno R. Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol. 2024;15:1321058. https:\/\/doi.org\/10.3389\/fneur.2024.1321058.","journal-title":"Front Neurol"},{"key":"3804_CR12","doi-asserted-by":"publisher","unstructured":"Luo S, Jiang Q, Zeng W, Wang Q, Zou Z, Yu Y, et al. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024. https:\/\/doi.org\/10.1002\/acn3.52142.","DOI":"10.1002\/acn3.52142"},{"issue":"7","key":"3804_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"issue":"8","key":"3804_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt-2022-0298","volume":"15","author":"A Sivadasan","year":"2023","unstructured":"Sivadasan A, Bril V. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis. Immunotherapy. 2023;15(8):553\u201363. https:\/\/doi.org\/10.2217\/imt-2022-0298.","journal-title":"Immunotherapy"},{"issue":"10","key":"3804_CR15","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"issue":"5","key":"3804_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jca.22002","volume":"37","author":"MH Tran","year":"2022","unstructured":"Tran MH. \u201cPlasma exchange in a bottle\u201d: An overview of efgartigimod for apheresis practitioners. J Clin Apher. 2022;37(5):512\u20135. https:\/\/doi.org\/10.1002\/jca.22002.","journal-title":"J Clin Apher"},{"issue":"2","key":"3804_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","volume":"14","author":"JF Liu","year":"2010","unstructured":"Liu JF, Wang WX, Xue J, Zhao CB, You HZ, Lu JH, et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial. 2010;14(2):153\u201360. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00751.x.","journal-title":"Ther Apher Dial"},{"issue":"1","key":"3804_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918.","journal-title":"Neurohospitalist"},{"issue":"12","key":"3804_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","volume":"42","author":"E Arsura","year":"1985","unstructured":"Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol. 1985;42(12):1149\u201353. https:\/\/doi.org\/10.1001\/archneur.1985.04060110031011.","journal-title":"Arch Neurol"},{"key":"3804_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","volume":"63","author":"L Wang","year":"2019","unstructured":"Wang L, Xi J, Zhang S, Wu H, Zhou L, Lu J, et al. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis. J Clin Neurosci. 2019;63:160\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2019.02.004.","journal-title":"J Clin Neurosci"},{"issue":"7","key":"3804_CR21","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000201501","volume":"100","author":"V Bril","year":"2023","unstructured":"Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, et al. Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis. Neurology. 2023;100(7):e671\u201382. https:\/\/doi.org\/10.1212\/WNL.0000000000201501.","journal-title":"Neurology"},{"key":"3804_CR22","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama M, Okada K, Masuda M, Shimizu Y, Yokoyama K, Uzawa A, et al. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord. 2020;13:1756286420904207. https:\/\/doi.org\/10.1177\/1756286420904207.","journal-title":"Ther Adv Neurol Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03804-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:28:21Z","timestamp":1724412501000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03804-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3804"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03804-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for ethical approval was waived by the Ethics Committee of Minaminara General Medical Center. This study was conducted in accordance with local legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and her daughter for the publication of any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HO received contracts and honoraria from Otsuka Co., Ltd., Alexion Co., Ltd., UCB Japan Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Tanabe Mitsubishi Co. Ltd., Sumitomo Pharma Co., Ltd, FP Pharma Co. Ltd, and Argenix Co. Ltd. MK received contracts and honoraria from Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., and UCB Japan Co., Ltd. MK is an Editorial Board Member for BMC Neurology.\u00a0The remaining authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}